Process development for adoptive cell therapy in academia: a pipeline for clinical-scale manufacturing of multiple TCR-T cell products

Cellular immunotherapies based on T cell receptor (TCR) transfer are promising approaches for the treatment of cancer and chronic viral infections. The discovery of novel receptors is expanding considerably; however, the clinical development of TCR-T cell therapies still lags. Here we provide a pipe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Silva, Daniela (VerfasserIn) , Chrobok, Michael (VerfasserIn) , Rovesti, Giulia (VerfasserIn) , Healy, Katie (VerfasserIn) , Wagner, Arnika Kathleen (VerfasserIn) , Maravelia, Panagiota (VerfasserIn) , Gatto, Francesca (VerfasserIn) , Mazza, Massimiliano (VerfasserIn) , Mazzotti, Lucia (VerfasserIn) , Lohmann, Volker (VerfasserIn) , Sällberg Chen, Margaret (VerfasserIn) , Sällberg, Matti (VerfasserIn) , Buggert, Marcus (VerfasserIn) , Pasetto, Anna (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 16 June 2022
In: Frontiers in immunology
Year: 2022, Jahrgang: 13, Pages: 1-16
ISSN:1664-3224
DOI:10.3389/fimmu.2022.896242
Online-Zugang:Resolving-System, kostenfrei, Volltext: https://doi.org/10.3389/fimmu.2022.896242
Verlag, kostenfrei, Volltext: https://www.frontiersin.org/articles/10.3389/fimmu.2022.896242
Volltext
Verfasserangaben:Daniela Nascimento Silva, Michael Chrobok, Giulia Rovesti, Katie Healy, Arnika Kathleen Wagner, Panagiota Maravelia, Francesca Gatto, Massimiliano Mazza, Lucia Mazzotti, Volker Lohmann, Margaret Sällberg Chen, Matti Sällberg, Marcus Buggert and Anna Pasetto

MARC

LEADER 00000caa a2200000 c 4500
001 1811985890
003 DE-627
005 20231004112548.0
007 cr uuu---uuuuu
008 220729s2022 xx |||||o 00| ||eng c
024 7 |a 10.3389/fimmu.2022.896242  |2 doi 
035 |a (DE-627)1811985890 
035 |a (DE-599)KXP1811985890 
035 |a (OCoLC)1341464516 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Silva, Daniela  |e VerfasserIn  |0 (DE-588)1263881394  |0 (DE-627)1811986854  |4 aut 
245 1 0 |a Process development for adoptive cell therapy in academia  |b a pipeline for clinical-scale manufacturing of multiple TCR-T cell products  |c Daniela Nascimento Silva, Michael Chrobok, Giulia Rovesti, Katie Healy, Arnika Kathleen Wagner, Panagiota Maravelia, Francesca Gatto, Massimiliano Mazza, Lucia Mazzotti, Volker Lohmann, Margaret Sällberg Chen, Matti Sällberg, Marcus Buggert and Anna Pasetto 
264 1 |c 16 June 2022 
300 |a 16 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 29.07.2022 
520 |a Cellular immunotherapies based on T cell receptor (TCR) transfer are promising approaches for the treatment of cancer and chronic viral infections. The discovery of novel receptors is expanding considerably; however, the clinical development of TCR-T cell therapies still lags. Here we provide a pipeline for process development and clinical-scale manufacturing of TCR-T cells in academia. We utilized two TCRs specific for hepatitis C virus (HCV) as models because of their marked differences in avidity and functional profile in TCR-redirected cells. With our clinical-scale pipeline, we reproduced the functional profile associated with each TCR. Moreover, the two TCR-T cell products demonstrated similar yield, purity, transduction efficiency as well as phenotype. The TCR-T cell products had a highly reproducible yield of over 1.4 × 109 cells, with an average viability of 93%; 97.8-99% of cells were CD3+, of which 47.66 ± 2.02% were CD8+ T cells; the phenotype was markedly associated with central memory (CD62L+CD45RO+) for CD4+ (93.70 ± 5.23%) and CD8+ (94.26 ± 4.04%). The functional assessments in 2D and 3D cell culture assays showed that TCR-T cells mounted a polyfunctional response to the cognate HCV peptide target in tumor cell lines, including killing. Collectively, we report a solid strategy for the efficient large-scale manufacturing of TCR-T cells. 
700 1 |a Chrobok, Michael  |e VerfasserIn  |4 aut 
700 1 |a Rovesti, Giulia  |e VerfasserIn  |4 aut 
700 1 |a Healy, Katie  |e VerfasserIn  |4 aut 
700 1 |a Wagner, Arnika Kathleen  |e VerfasserIn  |4 aut 
700 1 |a Maravelia, Panagiota  |e VerfasserIn  |4 aut 
700 1 |a Gatto, Francesca  |e VerfasserIn  |4 aut 
700 1 |a Mazza, Massimiliano  |e VerfasserIn  |0 (DE-588)1288739885  |0 (DE-627)1844838870  |4 aut 
700 1 |a Mazzotti, Lucia  |e VerfasserIn  |4 aut 
700 1 |a Lohmann, Volker  |e VerfasserIn  |0 (DE-588)1060228807  |0 (DE-627)799317136  |0 (DE-576)416317537  |4 aut 
700 1 |a Sällberg Chen, Margaret  |e VerfasserIn  |4 aut 
700 1 |a Sällberg, Matti  |e VerfasserIn  |4 aut 
700 1 |a Buggert, Marcus  |e VerfasserIn  |4 aut 
700 1 |a Pasetto, Anna  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Frontiers in immunology  |d Lausanne : Frontiers Media, 2010  |g 13(2022), Artikel-ID 896242, Seite 1-16  |h Online-Ressource  |w (DE-627)657998354  |w (DE-600)2606827-8  |w (DE-576)343624834  |x 1664-3224  |7 nnas  |a Process development for adoptive cell therapy in academia a pipeline for clinical-scale manufacturing of multiple TCR-T cell products 
773 1 8 |g volume:13  |g year:2022  |g elocationid:896242  |g pages:1-16  |g extent:16  |a Process development for adoptive cell therapy in academia a pipeline for clinical-scale manufacturing of multiple TCR-T cell products 
856 4 0 |u https://doi.org/10.3389/fimmu.2022.896242  |x Resolving-System  |x Verlag  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.frontiersin.org/articles/10.3389/fimmu.2022.896242  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20220729 
993 |a Article 
994 |a 2022 
998 |g 1060228807  |a Lohmann, Volker  |m 1060228807:Lohmann, Volker  |d 910000  |d 911700  |d 50000  |e 910000PL1060228807  |e 911700PL1060228807  |e 50000PL1060228807  |k 0/910000/  |k 1/910000/911700/  |k 0/50000/  |p 10 
998 |g 1288739885  |a Mazza, Massimiliano  |m 1288739885:Mazza, Massimiliano  |d 910000  |d 910100  |e 910000PM1288739885  |e 910100PM1288739885  |k 0/910000/  |k 1/910000/910100/  |p 8 
999 |a KXP-PPN1811985890  |e 4173748906 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Daniela Nascimento Silva, Michael Chrobok, Giulia Rovesti, Katie Healy, Arnika Kathleen Wagner, Panagiota Maravelia, Francesca Gatto, Massimiliano Mazza, Lucia Mazzotti, Volker Lohmann, Margaret Sällberg Chen, Matti Sällberg, Marcus Buggert and Anna Pasetto"]},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"16 June 2022"}],"recId":"1811985890","id":{"doi":["10.3389/fimmu.2022.896242"],"eki":["1811985890"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"given":"Daniela","display":"Silva, Daniela","role":"aut","family":"Silva"},{"given":"Michael","role":"aut","family":"Chrobok","display":"Chrobok, Michael"},{"display":"Rovesti, Giulia","role":"aut","family":"Rovesti","given":"Giulia"},{"role":"aut","family":"Healy","display":"Healy, Katie","given":"Katie"},{"display":"Wagner, Arnika Kathleen","family":"Wagner","role":"aut","given":"Arnika Kathleen"},{"given":"Panagiota","role":"aut","family":"Maravelia","display":"Maravelia, Panagiota"},{"given":"Francesca","role":"aut","family":"Gatto","display":"Gatto, Francesca"},{"display":"Mazza, Massimiliano","family":"Mazza","role":"aut","given":"Massimiliano"},{"given":"Lucia","role":"aut","family":"Mazzotti","display":"Mazzotti, Lucia"},{"given":"Volker","display":"Lohmann, Volker","role":"aut","family":"Lohmann"},{"given":"Margaret","display":"Sällberg Chen, Margaret","role":"aut","family":"Sällberg Chen"},{"role":"aut","family":"Sällberg","display":"Sällberg, Matti","given":"Matti"},{"display":"Buggert, Marcus","role":"aut","family":"Buggert","given":"Marcus"},{"display":"Pasetto, Anna","family":"Pasetto","role":"aut","given":"Anna"}],"note":["Gesehen am 29.07.2022"],"language":["eng"],"physDesc":[{"extent":"16 S."}],"title":[{"title_sort":"Process development for adoptive cell therapy in academia","subtitle":"a pipeline for clinical-scale manufacturing of multiple TCR-T cell products","title":"Process development for adoptive cell therapy in academia"}],"relHost":[{"pubHistory":["1.2010 -"],"note":["Gesehen am 07.11.13"],"language":["eng"],"id":{"zdb":["2606827-8"],"eki":["657998354"],"issn":["1664-3224"]},"recId":"657998354","type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Process development for adoptive cell therapy in academia a pipeline for clinical-scale manufacturing of multiple TCR-T cell productsFrontiers in immunology","origin":[{"dateIssuedKey":"2010","publisherPlace":"Lausanne","dateIssuedDisp":"2010-","publisher":"Frontiers Media"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Frontiers in immunology","title":"Frontiers in immunology"}],"part":{"pages":"1-16","text":"13(2022), Artikel-ID 896242, Seite 1-16","year":"2022","volume":"13","extent":"16"}}]} 
SRT |a SILVADANIEPROCESSDEV1620